Xanodyne Pharmaceuticals, a specialty pharma focused on women’s healthcare and pain management, announced the appointment of Michael Valentino to president and CEO. Valentino was previously president and CEO at Adams Laboratories. Before that, he was EVP, global head, consumer pharmaceuticals at Novartis.
Astellas hired Betsy Garofalo as global therapy leader for its central nervous system (CNS) group. Garofalo, a pediatric neurologist and epileptologist, will “provide strategic direction and leadership for the development of all Astellas CNS compounds,” said Steven Ryder, president of Astellas Pharma Global Development, in a statement. Garofalo is an adjunct associate professor of pediatrics at the University of Michigan, and has previously worked at Pfizer R&D, and Parke-Davis.
